How do you approach treatment for patients with proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) with end-stage renal disease who are considering kidney transplant?

Most patients with PGNMID have no detectable disease in their marrow or blood and urine protein cannot adequately be monitored.

Answer from: Medical Oncologist at Community Practice

Monoclonal gammopathy of renal significance includes a variety of renal pathologies: MIDD (LCDD, LHCDD, HCDD). Monoclonal immunotactoid glomerulonephritis or type 1 cryoglobulinemic glomerulonephritis. Light chain proximal tubulopathy or crystal-storing histiocytosis. C3 glomerulopathy with mono...

Comments

Medical Oncologist at University of Chicago
This is a great explanation. That’s the tric...

Medical Oncologist at Texas Oncology Dallas
I had a patient with PGNMID associated with mantle...

Medical Oncologist at Henry Ford Health System
I have two patients being treated for amyloidosis ...

Please select the option that best describes you:

How do you approach treatment for patients with proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) with end-stage renal disease who are considering kidney transplant?

Related Questions